An increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems.
As per WHO, 235 m people suffer from asthma globally. Majority of the asthma related deaths occur in middle- to low-income countries due to lack of treatment options.
This shows the potential demand for pulmonary drug delivery systems in the coming years.
Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market.
These advancements include incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.
Furthermore, rise in number of public and private organizations is another major factor propelling the growth of pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology.
Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting overall market growth.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon